Agilent Technologies enters its May 26 earnings report with a setup that is less about positioning risk and more about validating a recovery story the Street still broadly believes in — but at a lower price.
The analyst picture is the most telling angle here. Despite a persistent wave of target cuts over the past four months, every firm that trimmed has held its positive rating. Barclays lowered its target from $150 to $140 in mid-April while keeping Overweight. Morgan Stanley cut from $180 to $160 in early March and stayed Overweight. TD Cowen, UBS, Wells Fargo, and Evercore all trimmed targets in late February — all while maintaining Buy or Outperform calls. The direction of travel is clear: analysts still see meaningful upside from current levels, with the consensus mean near $161 against a close of $114.96, but they are quietly de-risking their assumptions ahead of each print. The stock is 40% below that consensus target, a gap wide enough to reflect either a genuine opportunity or structural concern about near-term delivery.
The stock itself has had a difficult month. Down roughly 6% over four weeks and now below $115, Agilent has given back ground even as the broader sector edged higher. The one-week recovery of about 3% looks modest against that backdrop. Peers tell a similar story directionally — and each rose around 5-6% on the week, while posted nearly 10%, suggesting the life sciences tools group has found some footing but Agilent has underperformed on the snapback.
Short sellers are not the driver of this story. Short Interest is just 1.7% of the free float — low by any measure — and has edged down fractionally over the past week. Borrow costs are negligible at 0.27%, and availability is essentially unlimited, pointing to no pressure from the lending market whatsoever. Options positioning backs that reading: the put/call ratio of 0.73 is almost exactly in line with its 20-day average, with a z-score close to zero. There is no notable hedging build ahead of the print.
The forward earnings picture offers one genuine point of tension. The 12-month forward EPS growth estimate ranks in the 90th percentile of the universe — an unusually strong growth signal for a stock that has been trading in a sustained downtrend. Earnings surprise history has been weak (34th percentile), meaning the company has tended to miss or barely meet recently. The May 26 print will test whether Agilent's growth trajectory is recovering in practice, or whether forward estimates have simply not yet caught up with a more cautious operating reality.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
